Clinical Trials Logo

Clinical Trial Summary

This is a cross-sectional pilot study designed to establish hot and cold cognitive functions and underlying neurocircuitry in older adults with MDD. The investigators will study 60 participants aged 21-80 years old with MDD. All participants will undergo clinical and neurocognitive assessment, and Magnetoencephalography (MEG)/Magnetic resonance imaging (MRI) procedures at one time point. The investigators will also enroll 60 demographically matched comparable, never-depressed healthy participants (controls) to establish cognitive benchmarks. Healthy controls will complete clinical and neurocognitive measures at one time point. To attain a balanced sample of adults across the lifespan, the investigators will enroll participants such that each age epoch (e.g., 21-30, 31-40, etc.) has a total of ten subjects (n=10) in both the healthy control cohort and depressed cohort.


Clinical Trial Description

Major depressive disorder (MDD) is a common, chronic, and disabling disorder that affects individuals across the lifespan. Research has consistently found that a core domain of MDD is cognitive dysfunction, with the majority of clinical research focusing on cold cognitive functions such as attention, memory, and executive function. However, emotional "hot" cognitive impairments are also frequently observed in domains such as emotion processing, impulsivity, reward processing, and social cognition, and as with cold cognitive processes, have been implicated in both disease course and treatment outcomes. The nomenclature of "cold" and "hot" cognitive function has been used to differentiate between those functions that are less influenced by emotional stimuli and/or processes (i.e., "cold" cognitive function) and those that have an emotional component and/or influence (i.e., "hot" cognitive function). The delineation of cold and hot cognitive function has critical implications for new mechanistic explanations and targeted antidepressant treatment development. Other researchers have proposed a testable cognitive neuropsychological model of MDD that describes the interaction of both cold and hot cognitive functions, underlying neurocircuitry, and proposed associated treatments. Despite ample evidence of impairments associated with hot cognitive processes, behaviors, and associated neural circuity, there is significantly limited information regarding hot cognitive function in adults across the lifespan with MDD. Prior research has been limited by 1) measurement of only one or two hot cognitive functions, 2) no integration of cold and hot cognitive function assessment, and 3) sparse information on hot cognition and associated neurocircuitry in adults over the age of 60. Given the importance of cognitive dysfunction and aging on disease course and overall functioning in MDD, it is critical to identify mechanisms of action and targeted treatment approaches that will improve cognition to achieve the ultimate goal of improving overall disease course, functioning, and quality of life. Identification of brain network alterations associated with particular hot cognitive functions and treatments that modify these regions will move us closer toward personalized medicine and improved patient outcomes. A first critical step in this endeavor is to better characterize hot cognitive dysfunctions in MDD, their relationship to cold cognitive dysfunctions, potential effects of age on these dysfunctions, and information on the associated underlying neurocircuitry in older adults. In the proposed preliminary study, 60 adults across the lifespan with MDD will complete clinical and cognitive measures, and MEG at one time-point. The investigators will also enroll 60 demographically matched comparable never-depressed healthy controls to establish cognitive benchmarks. The investigators will use existing healthy control data to establish resting-state and task-based MEG benchmarks. The study aims are: Aim 1. Establish and integrate hot and cold cognitive dysfunction in adults across the lifespan. H1.1. Adults with MDD compared to healthy controls will have significantly greater hot and cold cognitive dysfunction as measured by a Neuropsychological Test Battery to Evaluate Emotion, Motivation, Impulsivity, and Social Cognition (EMOTICOM) and the California Verbal Learning Test - Third Edition (CVLT-3)/Delis-Kaplan Executive Function System (D-KEFS), respectively. H1.2. Age will be associated with greater hot and cold cognitive dysfunction. Aim 2. Establish and compare specific brain networks underlying hot and cold cognitive tasks. H2.1. EMOTICOM Emotion Recognition and Categorization task scores will be associated with resting-state and task-based MEG connectivity metrics in the salience network, ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05966532
Study type Observational
Source University of Texas Southwestern Medical Center
Contact Shawn McClintock, PhD
Phone 214-648-2806
Email shawn.mcclintock@utsouthwestern.edu
Status Recruiting
Phase
Start date December 11, 2023
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT05416957 - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Phase 1
Active, not recruiting NCT03642964 - A Study in Patients With Major Depressive Disorder Phase 2
Terminated NCT01111565 - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT01912196 - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT00958204 - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression Phase 3
Completed NCT00102492 - Study Of GW679769 In Major Depressive Disorder Phase 2
Completed NCT02012218 - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Phase 3
Completed NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Phase 4
Completed NCT00768430 - Optimization of IV Ketamine for Treatment Resistant Depression Phase 2
Completed NCT00559299 - Patient Tolerability Study of GSK163090 Phase 1
Terminated NCT01123707 - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT04403373 - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study N/A
Completed NCT05541302 - Retrospective TMS Therapy for Adults With MDD
Recruiting NCT06385405 - Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment N/A
Completed NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan Phase 2
Recruiting NCT03012724 - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) N/A
Not yet recruiting NCT02395263 - Comparison of Yuxintine With Placebo in Treatment of MDD Phase 2
Completed NCT02380066 - Comparison of Anyu Peibo With Placebo in Treatment of MDD Phase 2
Completed NCT01187407 - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Phase 3